Loading...
Market
Will EMA finalize the label update for Wegovy to include heart failure benefits by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
European Medicines Agency (EMA) official website and press releases
Story
Novo Nordisk's GLP-1 Wegovy Receives EMA Approval for Heart Failure Label Update on Thursday
Sep 19, 2024, 08:00 PM
Novo Nordisk, the Danish drugmaker, announced that its drug Wegovy has received a positive opinion from the European Medicines Agency for a label update. The update will reflect reduced heart failure symptoms and improved physical function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The recommendation, announced on Thursday, is based on results from the STEP HFpEF trials. Wegovy is the first GLP-1 medication to receive such an endorsement for obesity-related heart failure.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%